Skip to main content

In Brief This Week: Siemens Healthineers, Luminex, BioReference Laboratories, and More

NEW YORK – Siemens Healthineers said this week that it has acquired Dutch point-of-care firm Minicare for an undisclosed amount. Based in Eindhoven, the Netherlands, Minicare develops handheld technology for immunoassay testing at the point of care. It has 15 employees. The deal closed in early July, Siemens Healthineers said.


Luminex said this week that the price of acquiring EMD Millipore's flow cytometry portfolio decreased by $1.9 million.

In a filing with the US Securities and Exchange Commission, the firm said that a purchase price reconciliation was completed during the first quarter of this year, leading to a revised amount of $68 million paid under a purchase agreement.

In 2018, Austin, Texas-based Luminex agreed to acquire the flow cytometry portfolio for $75 million, consisting of about $69.9 million to be paid under a stock and asset purchase agreement and about $5.1 million in committed inventory purchases, with both being subject to adjustment.

Luminex said in the SEC filing this week that it anticipates completing inventory purchases in the third quarter. The firm financed the acquisition with cash on hand.


BioReference Laboratories this week announced it has been selected as a preferred provider of laboratory services by the IPA Association of America, a trade association serving independent and integrated physician associations. The trade association also selected BioReference to assist with data analytics for its members' patients.

The agreement is designed to offer collaborative health management tools to the trade association's members, including more than 667 medical organizations representing more than 303,000 medical doctors in 39 states, BioReference said.

The trade association's members will now have access to the Elmwood Park, New Jersey-based firm's laboratory testing menu — including frequently requested routine and specialty tests and the 4Kscore, a blood test for detecting aggressive prostate cancer. 

Financial and other terms of the agreement were not disclosed.


LexaGene this week said that the US Centers for Disease Control and Prevention and the Food and Drug Administration's Antibiotic Resistance Isolate Bank has recognized it as a facility approved to receive samples for testing antibiotic resistance. The CDC and FDA AR Bank will provide information to LexaGene that will support the development of its LX Analyzer platform and address antibiotic resistance. According to LexaGene, it now has access to a repository of fully characterized pathogens that it will use to improve the LX Analyzer's detection capabilities. 


iCubate announced that the company’s iC-Myco Assay for the detection and identification of potentially pathogenic non-tuberculosis Mycobacterium (NTM) has been granted Breakthrough Device designation by the US Food and Drug Administration.

The iC-Myco Assay — a qualitative, multiplexed diagnostic test — identifies six of the most common NTM species that cause pulmonary infections, Mycobacterium abscessus, Mycobacterium avium, Mycobacterium chelonae, Mycobacterium fortuitum,  Mycobacterium intracellulare and Mycobacterium kansasii.


Castle Biosciences this week closed its initial public offering of 4.6 million shares of its common stock, including 600,000 shares sold to the offering's underwriters at $16 per share when they exercised their option to purchase additional shares. Gross proceeds from the IPO were $73.6 million. Castle Bio went public last week on the Nasdaq under the ticker symbol CSTL.


In Brief This Week is a selection of news items that may be of interest to our readers but had not previously appeared on 360Dx.